vs
Side-by-side financial comparison of CollPlant Biotechnologies Ltd (CLGN) and Envoy Medical, Inc. (COCH). Click either name above to swap in a different company.
CollPlant Biotechnologies Ltd is the larger business by last-quarter revenue ($179.0K vs $75.0K, roughly 2.4× Envoy Medical, Inc.). CollPlant Biotechnologies Ltd runs the higher net margin — -1869.8% vs -8781.3%, a 6911.5% gap on every dollar of revenue. On growth, Envoy Medical, Inc. posted the faster year-over-year revenue change (78.6% vs -28.1%).
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
Envoy Medical, Inc. is a medical technology firm specializing in developing and commercializing advanced implantable hearing solutions for sensorineural hearing loss patients. Its core products include fully implanted middle ear hearing devices, with primary markets across North America and Europe, serving users who gain limited benefit from conventional external hearing aids.
CLGN vs COCH — Head-to-Head
Income Statement — Q2 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $179.0K | $75.0K |
| Net Profit | $-3.3M | $-6.6M |
| Gross Margin | -3.9% | -181.3% |
| Operating Margin | -1775.4% | -8513.3% |
| Net Margin | -1869.8% | -8781.3% |
| Revenue YoY | -28.1% | 78.6% |
| Net Profit YoY | 20.5% | -42.6% |
| EPS (diluted) | $0.28 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $75.0K | ||
| Q3 25 | — | $42.0K | ||
| Q2 25 | $179.0K | $78.0K | ||
| Q1 25 | — | $46.0K | ||
| Q4 24 | — | $42.0K | ||
| Q3 24 | — | $56.0K | ||
| Q2 24 | $249.0K | $68.0K | ||
| Q1 24 | — | $59.0K |
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $-6.5M | ||
| Q2 25 | $-3.3M | $-5.7M | ||
| Q1 25 | — | $-5.0M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | — | $-6.0M | ||
| Q2 24 | $-4.2M | $-3.9M | ||
| Q1 24 | — | $-6.3M |
| Q4 25 | — | -181.3% | ||
| Q3 25 | — | -383.3% | ||
| Q2 25 | -3.9% | -200.0% | ||
| Q1 25 | — | -391.3% | ||
| Q4 24 | — | -273.8% | ||
| Q3 24 | — | -233.9% | ||
| Q2 24 | -115.3% | -260.3% | ||
| Q1 24 | — | -159.3% |
| Q4 25 | — | -8513.3% | ||
| Q3 25 | — | -13590.5% | ||
| Q2 25 | -1775.4% | -6500.0% | ||
| Q1 25 | — | -11102.2% | ||
| Q4 24 | — | -10828.6% | ||
| Q3 24 | — | -8878.6% | ||
| Q2 24 | -1769.5% | -7135.3% | ||
| Q1 24 | — | -8278.0% |
| Q4 25 | — | -8781.3% | ||
| Q3 25 | — | -15433.3% | ||
| Q2 25 | -1869.8% | -7294.9% | ||
| Q1 25 | — | -10865.2% | ||
| Q4 24 | — | -10995.2% | ||
| Q3 24 | — | -10642.9% | ||
| Q2 24 | -1690.8% | -5804.4% | ||
| Q1 24 | — | -10627.1% |
| Q4 25 | — | $-0.27 | ||
| Q3 25 | — | $-0.35 | ||
| Q2 25 | $0.28 | $-0.32 | ||
| Q1 25 | — | $-0.29 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | $0.37 | $-0.29 | ||
| Q1 24 | — | $-0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $12.5M | $-12.2M |
| Total Assets | $17.4M | $8.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $11.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-12.2M | ||
| Q3 25 | — | $-7.7M | ||
| Q2 25 | $12.5M | $-29.9M | ||
| Q1 25 | — | $-24.2M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-18.5M | ||
| Q2 24 | $20.7M | $-12.4M | ||
| Q1 24 | — | $-7.4M |
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $17.4M | $9.9M | ||
| Q1 25 | — | $10.4M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $26.6M | $6.7M | ||
| Q1 24 | — | $8.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.7M |
| Free Cash FlowOCF − Capex | — | $-5.9M |
| FCF MarginFCF / Revenue | — | -7809.3% |
| Capex IntensityCapex / Revenue | — | 229.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-2.6M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $-5.6M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-5.7M |
| Q4 25 | — | -7809.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5719.2% | ||
| Q1 25 | — | -8110.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -6750.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9657.6% |
| Q4 25 | — | 229.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 13.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2066.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 184.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
